The FDA granted emergency use authorization today for an innovative COVID-19 viral antigen test developed with support from the NIH RADx Initiative.

The COVID-19 Testing Impact Calculator is a free resource that shows how different approaches to testing and other mitigation measures, such as mask use, can curb the spread of the virus in any organization.

NIH, working in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), today announced a third round of contract awards for scale-up and manufacturing of new COVID-19 testing technologies.

NIH has awarded seven contracts to companies and academic institutions to develop digital health solutions that help address the COVID-19 pandemic.

NIH announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of RADx. These tests add to initial awards made to seven companies on July 31, 2020.

The winners of National Institutes of Health’s 9th annual Design by Biomedical Undergraduate Teams (DEBUT) challenge developed simple and low-cost diagnostics and treatments for conditions such as tuberculosis, cervical cancer, birth defects, and onchocerciasis (river blindness).

The National Institutes of Health has launched an ambitious effort to use artificial intelligence, computation, and medical imaging to enable early disease detection, inform successful treatment strategies, and predict individual disease outcomes of COVID-19.

NIH is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s RADx initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests.

In a paper in the New England Journal of Medicine, scientific leaders from the National Institutes of Health set forth a framework to increase significantly the number, quality and type of daily tests for detecting SARS-CoV-2, the virus that causes COVID-19, and help reduce inequities for underserved populations that have been disproportionally affected by the disease.